3 hours ago
Moderna (MRNA) Stock Drops 17% Despite Melanoma Trial Success
TLDR Moderna stock plunged more than 17% to $202.63 after early publication of its melanoma vaccine trial results. The Merck-Moder...
TLDR Moderna stock plunged more than 17% to $202.63 after early publication of its melanoma vaccine trial results. The Merck-Moder...